NO20090068L - Aktive agent formuleringer, fremstillingsmetoder, og anvendelsesmetoder - Google Patents

Aktive agent formuleringer, fremstillingsmetoder, og anvendelsesmetoder

Info

Publication number
NO20090068L
NO20090068L NO20090068A NO20090068A NO20090068L NO 20090068 L NO20090068 L NO 20090068L NO 20090068 A NO20090068 A NO 20090068A NO 20090068 A NO20090068 A NO 20090068A NO 20090068 L NO20090068 L NO 20090068L
Authority
NO
Norway
Prior art keywords
active agent
methods
compositions
application
agent formulations
Prior art date
Application number
NO20090068A
Other languages
English (en)
Inventor
Kristen Anne Arnold
Hengsheng Feng
Kurt R Nielsen
Original Assignee
Mutual Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutual Pharmaceutical Co Inc filed Critical Mutual Pharmaceutical Co Inc
Publication of NO20090068L publication Critical patent/NO20090068L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparater med aktivt middel omfattende partikler med aktivt middel som har en effektiv gjennomsnittlig partikkelstørrelse på mindre enn 2000 nm, hvor preparatene omfatter et partikkelsekvestreringsmiddel er beskrevet. Preparater som har en effektiv gjennomsnittlig partikkelstørrelse på mindre enn 2000 nm, hvor preparatene omfatter ingen tilsatte overflateaktive midler, fosfolipider eller kombinasjoner derav, er også beskrevet. I noen utførelsesformer er det aktive middelet fenofibrat. I andre utførelsesformer er fenofibratpreparater i en behandlingsform som er bioekvivalent med TriCor(r) 145 mg eller 48 mg.
NO20090068A 2006-06-26 2009-01-06 Aktive agent formuleringer, fremstillingsmetoder, og anvendelsesmetoder NO20090068L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80582306P 2006-06-26 2006-06-26
PCT/US2007/014818 WO2008002568A2 (en) 2006-06-26 2007-06-26 Active agent formulations, methods of making, and methods of use

Publications (1)

Publication Number Publication Date
NO20090068L true NO20090068L (no) 2009-03-23

Family

ID=38704788

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090068A NO20090068L (no) 2006-06-26 2009-01-06 Aktive agent formuleringer, fremstillingsmetoder, og anvendelsesmetoder

Country Status (14)

Country Link
US (2) US20080050450A1 (no)
EP (1) EP2037888A2 (no)
JP (1) JP2009541485A (no)
KR (1) KR20090045205A (no)
CN (1) CN101505733A (no)
AU (1) AU2007265452A1 (no)
BR (1) BRPI0713533A2 (no)
CA (1) CA2656277A1 (no)
CO (1) CO6150124A2 (no)
IL (1) IL196108A0 (no)
MX (1) MX2009000035A (no)
NO (1) NO20090068L (no)
RU (1) RU2009102262A (no)
WO (1) WO2008002568A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603013B2 (ja) * 2006-01-12 2014-10-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー ナノ粒子組成物およびその製法並びに使用法
US10100266B2 (en) 2006-01-12 2018-10-16 The Board Of Trustees Of The University Of Arkansas Dielectric nanolubricant compositions
BRPI0713533A2 (pt) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co formulações de agente ativo, métodos de fabricação, e métodos de uso
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US10752997B2 (en) 2006-10-19 2020-08-25 P&S Global Holdings Llc Methods and apparatus for making coatings using ultrasonic spray deposition
KR101478985B1 (ko) 2006-10-19 2015-01-06 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 정전기 스프레이를 사용하는 코팅 제조 방법 및 코팅 제조 장치
EP2296628B1 (en) 2008-05-22 2014-05-14 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
US9956170B2 (en) 2008-06-26 2018-05-01 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2309984B1 (en) 2008-07-02 2018-04-11 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2010078429A1 (en) * 2008-12-30 2010-07-08 Impax Laboratories, Inc. Pharmaceutical dosage forms and methods of manufacturing same
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
EA201390464A1 (ru) * 2010-09-28 2013-08-30 Рациофарм Гмбх Способ сухой обработки атазанавира
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
JP5824688B2 (ja) * 2011-05-24 2015-11-25 センカ株式会社 ｐＨ応答性高分子微粒子及びその分散体の製造方法
KR20200065093A (ko) * 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
US8486870B1 (en) 2012-07-02 2013-07-16 Ajay P. Malshe Textured surfaces to enhance nano-lubrication
US8476206B1 (en) 2012-07-02 2013-07-02 Ajay P. Malshe Nanoparticle macro-compositions
US9801820B2 (en) 2012-11-12 2017-10-31 New Jersey Institute Of Technology Pharmaceutical core-shell composite powder and processes for making the same
ES2847894T3 (es) * 2014-07-03 2021-08-04 Pfizer Nanopartículas terapéuticas dirigidas y procedimientos de fabricación y uso de las mismas
EP3668484B1 (en) * 2017-08-17 2022-07-13 F. Hoffmann-La Roche AG Novel pharmaceutical compositions for basic or neutral, low molecular weight compounds
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2586597A (en) * 1948-06-17 1952-02-19 Bell Telephone Labor Inc Oscillation generator
US2841138A (en) * 1957-03-11 1958-07-01 Ernest S V Laub Allergy testing device
US4058552A (en) * 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4228156C1 (de) * 1992-08-25 1993-10-21 Daimler Benz Ag Kraftstoffilteranordnung für eine Brennkraftmaschine
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
FR2721510B1 (fr) * 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
FR2742357B1 (fr) * 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6153525A (en) * 1997-03-13 2000-11-28 Alliedsignal Inc. Methods for chemical mechanical polish of organic polymer dielectric films
US6726934B1 (en) * 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
IL143197A0 (en) * 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1239831B1 (en) * 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
WO2001047501A1 (en) * 1999-12-29 2001-07-05 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US7153525B1 (en) * 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
CA2415643C (en) * 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7094810B2 (en) * 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
EP1467709A1 (en) * 2002-01-14 2004-10-20 Dow Global Technologies Inc. Drug nanoparticles from template emulsions
EP1517676A1 (en) * 2002-05-03 2005-03-30 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
AU2003291667A1 (en) * 2002-10-31 2004-06-07 Alza Corporation Pharmaceutical formulation providing an increased bioavailability of hydrophobic drugs
FR2855756B1 (fr) * 2003-06-06 2005-08-26 Ethypharm Sa Comprime orodispersible multicouche
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006060817A1 (en) * 2004-12-03 2006-06-08 Abbott Laboratories Pharmaceutical compositions
DE102004059792A1 (de) * 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
WO2007070082A1 (en) * 2005-05-10 2007-06-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising teprenone
EP2012751A4 (en) * 2006-03-21 2010-11-24 Morehouse School Of Medicine NEW NANOPARTICLES FOR THE ACTIVE COMPOSITION
BRPI0713533A2 (pt) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co formulações de agente ativo, métodos de fabricação, e métodos de uso
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use

Also Published As

Publication number Publication date
BRPI0713533A2 (pt) 2012-04-17
WO2008002568A2 (en) 2008-01-03
US20080050450A1 (en) 2008-02-28
CO6150124A2 (es) 2010-04-20
JP2009541485A (ja) 2009-11-26
IL196108A0 (en) 2009-09-01
EP2037888A2 (en) 2009-03-25
CN101505733A (zh) 2009-08-12
KR20090045205A (ko) 2009-05-07
CA2656277A1 (en) 2008-01-03
AU2007265452A1 (en) 2008-01-03
MX2009000035A (es) 2009-05-28
RU2009102262A (ru) 2010-08-10
US20080220076A1 (en) 2008-09-11
WO2008002568A3 (en) 2008-04-17
AU2007265452A2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
NO20090068L (no) Aktive agent formuleringer, fremstillingsmetoder, og anvendelsesmetoder
MX2009003002A (es) Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.
Choi et al. Removal and killing of multispecies endodontic biofilms by N-acetylcysteine
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
NZ573555A (en) Nanoparticulate posaconazole formulations
MY153658A (en) Methods of making compositions comprising films
RU2009149687A (ru) Фармацевтические композиции и способы лечения сухих кератитов
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
CL2015001960A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
DK1898876T3 (da) Mucoadhæsive xyloglucanholdige fprmuleringer anvendelige i medicinske anordninger og i farmaceutiske former
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
NO20064584L (no) Tetrahydropyridoindolderivater
AR057422A1 (es) Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
SI1933809T1 (sl) Sestavki za mazalno dajanje
AR052252A1 (es) Formulaciones topicas de nepafenac
NO20082536L (no) Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser
HRP20080677T3 (hr) Uporaba 3,11 b-cis-dihidrotetrabenazina u liječenju simptoma huntington-ove bolesti
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
DK1677777T3 (da) Pellets indeholdende venlafaxin-hydrochlorid
NO20075758L (no) Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin
WO2009102808A3 (en) Doxorubicin adjuvants to reduce toxicity and methods for using the same
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application